Compare · LHCG vs TOI
LHCG vs TOI
Side-by-side comparison of LHC Group (LHCG) and The Oncology Institute Inc. (TOI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LHCG and TOI operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- LHCG is the larger of the two at $3.72B, about 7.3x TOI ($512.9M).
- TOI has hit the wire 7 times in the past 4 weeks while LHCG has been quiet.
- LHCG has more recent analyst coverage (21 ratings vs 8 for TOI).
- Company
- LHC Group
- The Oncology Institute Inc.
- Price
- $169.80+0.47%
- $5.12+5.13%
- Market cap
- $3.72B
- $512.9M
- 1M return
- -
- -3.12%
- 1Y return
- -
- +46.70%
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2020
- News (4w)
- 0
- 7
- Recent ratings
- 21
- 8
LHC Group
LHC Group, Inc., a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. The company's Home Health Services segment offers home nursing services, including wound care and dressing changes, cardiac rehabilitation, infusion therapy, pain management, pharmaceutical administration, skilled observation and assessment, and patient education; medically-oriented social services; and physical, occupational, and speech therapy services. Its Hospice Services segment provides pain and symptom management accompanied by palliative medication, emotional and spiritual support, inpatient and respite care, homemaker services, dietary counseling, family bereavement counseling, and social worker visits. The company's Home and Community-Based Services segment offers range of services, such as assistance with grooming, medication reminders, meal preparation, assistance with feeding, light housekeeping, respite care, transportation, and errand services to patients in their home or in a medical facility. Its Facility-Based Services segment serves patients suffering from respiratory failure, neuromuscular and cardiac disorders, non-healing wounds, renal disorders, cancer, head and neck injuries, and mental disorders, as well as treats patients diagnosed with musculoskeletal impairments; and operates institutional pharmacy and other non-related facilities, nursing facilities, family health center, rural health clinic, and physician practice, as well as offers physical therapy services. The company's Healthcare Innovations (HCI) Services segment provides strategic health management services to accountable care organizations. As of December 31, 2020, it operated 537 home health services locations, 120 hospice locations, 124 community-based service locations, 11 long-term acute care hospitals with 12 locations, and 12 HCI locations. The company was founded in 1994 and is based in Lafayette, Louisiana.
The Oncology Institute Inc.
The Oncology Institute, Inc. provides cancer awareness, prevention, diagnosis, treatment, and education service. The company offers chemotherapy education, comprehensive lab testing, pain management, financial counseling, end of life counseling, dietary counseling, in-house infusion center, in-house support groups, in-house pharmacy, nutraceuticals, clinical trials, and educational seminars. It also operates the hope, health, and healing center to offer patients alternative and holistic treatments in addition to chemotherapy. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Latest LHCG
- SEC Form 4: Reed W Earl Iii returned $23,595,490 worth of shares to the company (138,797 units at $170.00), closing all direct ownership in the company
- SEC Form 4: Nixon Ronald T returned $4,607,000 worth of shares to the company (27,100 units at $170.00), closing all direct ownership in the company
- SEC Form 4: Azare Monica F returned $5,185,000 worth of shares to the company (30,500 units at $170.00), closing all direct ownership in the company
- SEC Form 4: Goldberg Jonathan returned $9,770,240 worth of shares to the company (57,472 units at $170.00), closing all direct ownership in the company
- SEC Form 4: Mackel Dale returned $3,066,630 worth of shares to the company (18,039 units at $170.00), closing all direct ownership in the company
- SEC Form 4: Indest John L returned $5,941,160 worth of shares to the company (34,948 units at $170.00), closing all direct ownership in the company
- SEC Form 4: Gachassin Nicholas Iii returned $2,696,200 worth of shares to the company (15,860 units at $170.00), closing all direct ownership in the company
- SEC Form 4: Proffitt Joshua L. returned $7,809,290 worth of shares to the company (117,443 units at $66.49), closing all direct ownership in the company
- SEC Form 4: Myers Keith G returned $136,814,640 worth of shares to the company (903,558 units at $151.42), closing all direct ownership in the company
- SEC Form 4: Seymour Kimberly S returned $264,180 worth of shares to the company (5,595 units at $47.22), closing all direct ownership in the company
Latest TOI
- Director Hively Brad sold $1,946,310 worth of shares (298,853 units at $6.51), decreasing direct ownership by 42% to 411,976 units (SEC Form 4)
- The Oncology Institute Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Large owner Chernett Jorey bought $78,480 worth of shares (12,000 units at $6.54), increasing direct ownership by 0.11% to 10,660,858 units (SEC Form 4)
- SEC Form 10-Q filed by The Oncology Institute Inc.
- The Oncology Institute Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- The Oncology Institute Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- The Oncology Institute Rebrands as Starling Oncology
- Director Kaushal Mohit was granted 33,133 shares, increasing direct ownership by 19% to 205,716 units (SEC Form 4)
- Director Mcgeorge Anne was granted 41,165 shares, increasing direct ownership by 14% to 332,535 units (SEC Form 4)
- Director Pacala Mark L was granted 30,120 shares, increasing direct ownership by 12% to 286,881 units (SEC Form 4)